Dr. Acostamadiedo studies how specific genetic changes can influence the parathyroid glands, which are crucial for managing calcium levels in the body. His work includes understanding conditions like hyperparathyroidism jaw-tumor syndrome. He also investigates pancreaticopleural fistula, a condition where a hole forms between the pancreas and the chest cavity, and looks at how imaging and endoscopic treatments can help diagnose and treat this problem effectively. Additionally, he evaluates advanced lung cancer treatment options and imaging techniques to measure cancer progression.
Key findings
In mice with a specific gene deletion related to the parathyroid gland, calcium and parathyroid hormone levels were lower, and the glands were smaller; the effects varied by mouse strain.
Imaging tests like CT scans were essential for diagnosing pancreaticopleural fistula quickly, with a case study showing successful treatment with a stent resulting in healing within about 9 weeks.
Whole body FDG-PET imaging agreed with traditional methods in 83% of cases when staging small cell lung cancer, enhancing the accuracy of treatment planning.
In a Phase II study of pyrazine diazohydroxide for advanced non-small-cell lung cancer, no patients showed improvement from treatment, with a median survival of only 6.6 months.
Frequently asked questions
Does Dr. Acostamadiedo study conditions related to the parathyroid glands?
Yes, he studies genetic changes affecting parathyroid glands and related disorders such as hyperparathyroidism jaw-tumor syndrome.
What treatments has Dr. Acostamadiedo researched for lung cancer?
He has researched the effectiveness of imaging techniques for lung cancer staging and investigated a drug called pyrazine diazohydroxide, which unfortunately did not show significant benefits for patients.
Is Dr. Acostamadiedo's work relevant for patients with pancreatic conditions?
Yes, his research on pancreaticopleural fistula focuses on improved diagnostic techniques and treatment options that directly benefit patients with related conditions.
How effective is FDG-PET in assessing lung cancer?
In Dr. Acostamadiedo's study, FDG-PET imaging was accurate in 83% of cases when staging small cell lung cancer, making it a reliable tool for doctors.
Publications in plain English
Phenotype of Parathyroid-targetedDeletion in Mice Is Strain-dependent.
2024
Journal of the Endocrine Society
Costa-Guda J, Cohen ST, Romano R, Acostamadiedo J, Clark K +2 more
Plain English This study looked at how specific genetic changes in mice affect the growth and function of parathyroid glands, which are important for regulating calcium levels in the body. Researchers found that mice with a targeted deletion of a certain gene had lower calcium and parathyroid hormone levels, along with smaller parathyroid glands, but this effect varied depending on the mouse strain. Understanding these differences helps to identify the underlying mechanisms of diseases like hyperparathyroidism jaw-tumor syndrome, which can affect human health.
Who this helps: This benefits researchers and doctors working on parathyroid disorders.
Pancreaticopleural Fistula: A Review of Imaging Diagnosis and Early Endoscopic Intervention.
2018
Case reports in gastrointestinal medicine
Kord Valeshabad A, Acostamadiedo J, Xiao L, Mar W, Xie KL
Plain English This research focused on a condition called pancreaticopleural fistula (PPF), where a hole forms between the pancreas and the pleural cavity in the chest, often due to pancreatitis. In a case study, a 49-year-old man with this condition experienced chest pain and breathing issues; tests showed high levels of a digestive enzyme in fluid from his chest and confirmed the fistula with imaging. He was successfully treated with a stent, and the fistula healed in about 9 weeks. The study highlights that using imaging tests like CT scans helps diagnose PPF quickly, and early endoscopic treatments can effectively address the issue without needing surgery.
Who this helps: This benefits patients with pancreatic conditions and their doctors.
Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.
2002
Lung cancer (Amsterdam, Netherlands)
Chin R, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J +4 more
Plain English This study examined the effectiveness of a type of imaging called FDG-PET for staging small cell lung cancer (SCLC) in 18 patients, comparing it to more traditional imaging methods like CT and MRI. The results showed that FDG-PET agreed with these other methods in 83% of cases, accurately identifying how far the cancer had spread in most patients. This is important because better staging can help doctors plan treatments and predict outcomes more effectively.
Who this helps: Patients with small cell lung cancer.
Phase II study of pyrazine diazohydroxide (NSC 361456) for advanced non small-cell lung cancer.
2000
Clinical lung cancer
Blackstock AW, Acostamadiedo J, Lesser G, Richards F, Case LD +1 more
Plain English This study tested a new drug called pyrazine diazohydroxide (PZDH) in patients with advanced non-small-cell lung cancer. Researchers found that out of 15 patients, none showed improvement from the treatment, and the median survival was only 6.6 months. The treatment caused some side effects, like low blood platelet counts, in six patients, but overall the drug didn’t have any real benefit for this group.
Who this helps: This information is particularly relevant for doctors and researchers looking for effective treatments for advanced lung cancer patients.